CINCINNATI--(BUSINESS WIRE)--May 31, 2018--
Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company
focused on advancing first-in-class treatments for ocular diseases,
today announced that Chief Executive Officer, Stephen Hoffman, M.D.,
Ph.D., will present at the Jefferies 2018 Global Healthcare Conference
on Friday, June 8, 2018 at 1:30 p.m. Eastern Time in New York, NY. Dr.
Hoffmann will provide a corporate overview and business update.
The presentation will be webcast live and may be accessed by visiting
Aerpio's website at http://ir.aerpio.com/.
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on
advancing first-in-class treatments for ocular diseases. The Company’s
lead compound, AKB‐9778, is a small molecule activator of the Tie2
pathway and is in clinical development for the treatment of
non-proliferative diabetic retinopathy. For more information please
View source version on businesswire.com: https://www.businesswire.com/news/home/20180531005453/en/
Source: Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc.
Michael Rogers, 513-985-1958